UK authorisation has been given for sotrovimab for patients with mild to moderate COVID-19 who are at risk of developing severe disease.
The Medicines and Healthcare products Regulatory Agency (MHRA) said that the single monoclonal antibody drug was a safe and effective treatment for reducing the risk of hospitalisation and death.
Results from a clinical trial, published as a preprint last month, suggested that a single dose of sotrovimab (Xevudy, GSK and Vir Biotechnology) reduced the risk of hospitalisation in high-risk adults for longer than 24 hours, or death within 29 days, by 79% (95% CI 50% to 91%) compared to placebo.
Sotrovimab works by binding to the spike protein on the outside of the COVID-19 virus to prevent it from attaching to and entering human cells.
https://www.medscape.co.uk/viewarticle/covid-antibody-treatment-sotrovimab-